Drugs / Interleukine-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02389231 | May 2017 → Nov 2018 | autoimmune hemolytic anemia | University Hospital, Bordeaux | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interleukine-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02389231 ↗ |
| Known as | Proleukin | “Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.” NCT02389231 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously for 5 days” NCT02389231 ↗ |